Empros Pharma has developed a revolutionary drug – EMP16

The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes towards the end of the small intestine. EMP16 is based on a proprietary advanced drug delivery technology, designed to have features that optimizes its effect throughout the gastrointestinal system.

EMP16 is an oral product with a local effect in the gastrointestinal systems. It is a fixed dose combination of two locally active, safe and established active drugs (orlistat and acarbose). The advanced multiple unit, modified release formulation is designed to maximize the effect of the drugs as well as improving tolerability.

Conventional orlistat

  • Orlistat inhibits breakdown of triglycerides and thereby the absorption of free fatty acids (“energy leaks out”)
  • Acarbose delays breakdown of carbohydrates and thereby prolongs the absorption of glucose (lowers insulin)
  • Unquestionable safety
  • Both have an unfavorable efficacy/tolerability ratio

Conventional acarbose


  • Delivery of the drug into targeted areas of the gastrointestinal tract
  • Increases efficacy
  • Maintained safety
  • Enables combination of orlistat and acarbose without tolerability issues
Novel and proprietary fixed combination of orlistat and acarbose with modified-release formulation effect and tolerability